Skip to content
Med Pharma News

Med Pharma News

Your Daily Dose of Pharma News

  • About Med Pharma News
  • Contact Us
  • News
  • Privacy Policy
  • Terms and Conditions
J&J Ollin acquisition OLN324 deal infographic
  • Industry Insights
1 hour ago1 hour ago

J&J Ollin Acquisition: $2.2B Bet on an Eye Drug Built to Beat Vabysmo

J&J will pay $2.2B upfront for Ollin Biosciences and its VEGF/Ang2 eye drug OLN324, with Blackstone funding $750M of Phase 3. Terms, science and risks.

  • Heidi Overton FDA Vote: One GOP Defection Could Sink the Commissioner Pick
  • Windward Bio IPO: $175M Raise Puts Twice-Yearly Asthma Antibody in the Spotlight
  • AstraZeneca Job Cuts: 600 US Sales Roles Go in $1.5B Savings Drive
CagriSema weight loss infographic showing 25.4% loss in early responders in REDEFINE 1
  • Pharmaceuticals
1 day ago1 day ago

CagriSema Weight Loss: Early Responders Lose 25% in New REDEFINE 1 Analysis

Novo Nordisk ObesityWeek data show CagriSema users who lost 5% by week 8 reached 25.4% weight loss at 68 weeks, ahead of an FDA decision due in Q4 2026.

  • Lilly ObesityWeek 2026 Data: EloraTZP Hits 23% Weight Loss, Retatrutide Tackles Sleep Apnea
  • China NRDL 2026: Pfizer and Innovent GLP-1s Win Coverage as 107 Drugs Join
  • Gazyva Membranous Nephropathy Approval: Roche Wins First FDA Nod in PMN
Lilly ObesityWeek 2026 infographic showing EloraTZP weight loss and retatrutide sleep apnea results
  • Pharmaceuticals
1 day ago

Lilly ObesityWeek 2026 Data: EloraTZP Hits 23% Weight Loss, Retatrutide Tackles Sleep Apnea

Lilly’s ObesityWeek 2026 slate: EloraTZP up to 23.3% weight loss in type 2 diabetes, retatrutide cuts sleep apnea events by up to 60.6%, Zepbound data in teens.

  • CagriSema Weight Loss: Early Responders Lose 25% in New REDEFINE 1 Analysis
  • China NRDL 2026: Pfizer and Innovent GLP-1s Win Coverage as 107 Drugs Join
  • Gazyva Membranous Nephropathy Approval: Roche Wins First FDA Nod in PMN
Heidi Overton FDA vote infographic showing Senate HELP Committee vote date and committee math
  • Industry Insights
2 days ago

Heidi Overton FDA Vote: One GOP Defection Could Sink the Commissioner Pick

The Senate HELP Committee votes on FDA commissioner nominee Heidi Overton on 18 November. Here is where senators stand, why pharma is watching and what happens if she stalls.

  • J&J Ollin Acquisition: $2.2B Bet on an Eye Drug Built to Beat Vabysmo
  • Windward Bio IPO: $175M Raise Puts Twice-Yearly Asthma Antibody in the Spotlight
  • AstraZeneca Job Cuts: 600 US Sales Roles Go in $1.5B Savings Drive
  • Industry Insights

Fortis Healthcare Acquisition: What ₹277 Crore for Suguna Hospital Says About Bengaluru Cluster Strategy

Megan Wood 1 hour ago1 hour ago
  • Healthcare IT

Healthcare AI Adoption Survey 2026: A Hospital Leader Checklist

Megan Wood 1 hour ago1 hour ago
J&J Ollin acquisition OLN324 deal infographic
  • Industry Insights

J&J Ollin Acquisition: $2.2B Bet on an Eye Drug Built to Beat Vabysmo

Megan Wood1 hour ago1 hour ago09 mins

J&J will pay $2.2B upfront for Ollin Biosciences and its VEGF/Ang2 eye drug OLN324, with Blackstone funding $750M of Phase 3. Terms, science and risks.

Read More
CagriSema weight loss infographic showing 25.4% loss in early responders in REDEFINE 1
  • Pharmaceuticals

CagriSema Weight Loss: Early Responders Lose 25% in New REDEFINE 1 Analysis

Megan Wood1 day ago1 day ago010 mins

Novo Nordisk ObesityWeek data show CagriSema users who lost 5% by week 8 reached 25.4% weight loss at 68 weeks, ahead of an FDA decision due in Q4 2026.

Read More
Lilly ObesityWeek 2026 infographic showing EloraTZP weight loss and retatrutide sleep apnea results
  • Pharmaceuticals

Lilly ObesityWeek 2026 Data: EloraTZP Hits 23% Weight Loss, Retatrutide Tackles Sleep Apnea

Megan Wood1 day ago010 mins

Lilly’s ObesityWeek 2026 slate: EloraTZP up to 23.3% weight loss in type 2 diabetes, retatrutide cuts sleep apnea events by up to 60.6%, Zepbound data in teens.

Read More
Heidi Overton FDA vote infographic showing Senate HELP Committee vote date and committee math
  • Industry Insights

Heidi Overton FDA Vote: One GOP Defection Could Sink the Commissioner Pick

Megan Wood2 days ago010 mins

The Senate HELP Committee votes on FDA commissioner nominee Heidi Overton on 18 November. Here is where senators stand, why pharma is watching and what happens if she stalls.

Read More
Windward Bio IPO infographic: $175M raised at $17 a share, $1.07B valuation, Sanofi $50M placement
  • Industry Insights

Windward Bio IPO: $175M Raise Puts Twice-Yearly Asthma Antibody in the Spotlight

Megan Wood2 days ago010 mins

Novo-backed Windward Bio raised $175M in its Nasdaq IPO, plus $50M from Sanofi, to fund WIN378, an anti-TSLP antibody aimed at twice-yearly dosing in asthma and COPD.

Read More
AstraZeneca job cuts infographic: 600 US sales roles, $1.5B annual savings target, up to $2B charges
  • Industry Insights

AstraZeneca Job Cuts: 600 US Sales Roles Go in $1.5B Savings Drive

Megan Wood2 days ago012 mins

AstraZeneca is cutting about 600 US respiratory and immunology sales jobs, Bloomberg reports, the first visible step in its $1.5 billion-a-year savings plan.

Read More
China NRDL 2026 infographic: 107 drugs added, 51 Class 1 innovative drugs, 3,331 total
  • Pharmaceuticals

China NRDL 2026: Pfizer and Innovent GLP-1s Win Coverage as 107 Drugs Join

Megan Wood2 days ago2 days ago09 mins

China’s 2026 reimbursement list adds 107 drugs, including Pfizer’s ecnoglutide and Innovent’s mazdutide for diabetes, from 1 January 2027.

Read More
Infographic: Gazyva membranous nephropathy FDA approval, 36% vs 6% complete remission in MAJESTY
  • Pharmaceuticals

Gazyva Membranous Nephropathy Approval: Roche Wins First FDA Nod in PMN

Megan Wood2 days ago09 mins

FDA approves Roche Gazyva as the first drug for primary membranous nephropathy after MAJESTY showed 36% complete remission vs 6% with tacrolimus.

Read More
Imfinzi Padcev bladder cancer FDA approval infographic with VOLGA trial results
  • Pharmaceuticals

Imfinzi Padcev Bladder Cancer Approval: AstraZeneca Takes On Keytruda in Cisplatin-Free Surgery Setting

Megan Wood3 days ago010 mins

The FDA approved perioperative Imfinzi plus Padcev for muscle-invasive bladder cancer patients who cannot take cisplatin. VOLGA cut the risk of death by 42%, and the approval pits AstraZeneca against Merck while Padcev wins either way.

Read More
  • 1
  • 2
  • 3
  • …
  • 61

Categories

  • Healthcare IT (26)
  • Industry Insights (351)
  • Lifestyle and Wellness (24)
  • Medical Devices (45)
  • Pharmaceuticals (105)
  • Uncategorized (1)

Recent Posts

  • J&J Ollin Acquisition: $2.2B Bet on an Eye Drug Built to Beat Vabysmo
  • CagriSema Weight Loss: Early Responders Lose 25% in New REDEFINE 1 Analysis
  • Lilly ObesityWeek 2026 Data: EloraTZP Hits 23% Weight Loss, Retatrutide Tackles Sleep Apnea
  • Heidi Overton FDA Vote: One GOP Defection Could Sink the Commissioner Pick
  • Windward Bio IPO: $175M Raise Puts Twice-Yearly Asthma Antibody in the Spotlight

You May Have Missed

Indoco Remedies AnaCipher ANVISA approval graphic about the India CRO industry
  • Pharmaceuticals

Indoco Remedies AnaCipher ANVISA Approval: What It Means for India CROs

Megan Wood 3 weeks ago
Genmab Rina-S platinum-resistant ovarian cancer 45.9 percent response rate featured graphic
  • Pharmaceuticals

Genmab Reports Positive Rina-S Data in Platinum-Resistant Ovarian Cancer

Megan Wood 1 month ago1 month ago
Karyotyping Market
  • Industry Insights

Karyotyping Market Revenue, Trends, and Strategic Insights by 2032

Megan Wood 9 months ago
Graphic: ICMR funding for medical devices with gold coin stacks and seven-centre grant
  • Medical Devices

ICMR Funding for Medical Devices: Major Rs 15 Cr Boost

Megan Wood 4 weeks ago4 weeks ago
Graphic: vaccine research ethics shown as a balance scale in purple with gold pans
  • Industry Insights

Vaccine Research Ethics: Lessons From Guinea-Bissau Trial

Megan Wood 3 weeks ago3 weeks ago
Pharmaceutical Market
  • Industry Insights

Pharmaceutical Market Revenue, Trends, and Strategic Insights by 2032

Megan Wood 9 months ago
Lab on Chip Market Revenue, Trends, and Strategic Insights by 2030
  • Industry Insights

Lab on Chip Market Revenue, Trends, and Strategic Insights by 2030

Megan Wood 6 months ago6 months ago
Neuralink brain chip implant device illustration
  • Medical Devices

Neuralink Brain Chip Implant Poised to Transform Human-Computer Interaction

Megan Wood 2 years ago1 month ago
Digital Newspaper - Multipurpose News WordPress Theme 2026. Powered By BlazeThemes.